We provided a robust analysis and a structured guide for serum biomarker deployment in MTC management, balancing established markers (i.e., calcitonin and CEA) and emerging tools to enhance clinical decision-making (i.e., ProCT, CA 19.9, ProGRP). Here, CEACAM5 is linked to medullary thyroid gland carcinoma.